Resistance Mechanisms to BCMA Targeting Bispecific Antibodies and CAR T-Cell Therapies in Multiple Myeloma
B-cell maturation antigen (BCMA)-targeted therapies including both chimeric antigen receptor (CAR) T-cell therapies and bispecific antibodies (BsAbs), have revolutionized the treatment landscape for relapsed/refractory multiple myeloma (MM), offering both deep and durable responses, even in heavily...
Saved in:
Main Authors: | Brandon Tedder, Manisha Bhutani |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2025-07-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/14/14/1077 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A roadmap to implementing outpatient administration of bispecific antibodies in multiple myeloma
by: Alfred L. Garfall, et al.
Published: (2025-07-01) -
TIGIT blockade in the context of BCMA-CART cell therapy does not augment efficacy in a multiple myeloma mouse model
by: Aina Oliver-Caldes, et al.
Published: (2025-12-01) -
Minimising Toxicity and Maximising Response: T-Cell Engagers for Elderly Patients with Multiple Myeloma
by: Anthony McLoughlin, et al.
Published: (2025-06-01) -
Deciphering the bone marrow microenvironment’s role in multiple myeloma immunotherapy resistance
by: Nicolas Thomas Iannozzi, et al.
Published: (2025-07-01) -
Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific antibody with trans-binding and enhanced target binding avidity
by: Xinghua Pang, et al.
Published: (2023-12-01)